Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

"It's cool to get the award, but what I submitted to it is so much more important to me," Cooper Taylor said about getting a ...